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Objectives:
 
 In this study we determined the incidence
and direct inpatient and outpatient costs of systemic
fungal infections (candidiasis, aspergillosis, cryptococ-
cosis, histoplasmosis) in 1998.
 
Methods:
 
 Using primarily the National Hospital Dis-
charge Survey (NHDS) for incidence and the Maryland
Hospital Discharge Data Set (MDHDDS) for costs, we
surveyed four systemic fungal infections in patients who
also had HIV/AIDS, neoplasia, transplant, and all other
concomitant diagnoses. Using a case-control method,
we compared the cases with controls (those without
fungal infections with the same underlying comorbid-
ity) to obtain the incremental hospitalization costs. We
 
used the Student’s 
 
t
 
-test to determine significance of in-
cremental hospital costs. We modeled outpatient costs
on the basis of discharge status to calculate the total an-
nual cost for systemic fungal infections in 1998.
 
Results:
 
 For 1998, the projected average incidence was
306 per million US population, with candidiasis ac-
counting for 75% of cases. The estimated total direct
cost was $2.6 billion and the average per-patient attrib-
utable cost was $31,200. The most commonly reported
comorbid diagnoses with fungal infections (HIV/AIDS,
neoplasms, transplants) accounted for only 45% of all
infections.
 
Conclusion:
 
 The cost burden is high for systemic fungal
infections. Additional attention should be given to the
55% with fungal disease and other comorbid diagnoses.
 
Keywords:
 
 aspergillosis, candidiasis, cryptococcosis, histo-
plasmosis.
 
Introduction
 
The impact of fungal infections on health care and
economic expenditures is large and of growing
concern. Data in the 1980s showed a dramatic in-
 
crease in nosocomial fungal infections in the United
States [1,2]. Despite this, there are few estimates
in the literature for the overall costs of fungal in-
fections. Costs attributable to systemic fungal in-
fections are difficult to estimate because they often
occur in conjunction with other diagnoses. Apart
from various cost-effectiveness studies of drugs to
treat fungal infections [3,4] and cost studies of
fungal infections in specific disease populations
[5,6], there has not been a general cost study of
systemic fungal infections over all diseases. We de-
termined the first-year direct costs of four systemic
fungal infections: candidiasis, aspergillosis, cryp-
tococcosis and histoplasmosis.
We also determined the annual incidence of
these four fungal infections in the United States.
Currently reported incidence rates are highly vari-
able [7,8] and apart from one regional population
study [9], consist mostly of nosocomial rates re-
ported voluntarily by hospitals [10,11]. Existing
studies focus primarily on one type of fungal in-
fection with a single comorbid diagnosis [12–14].
The study presented here uses relatively large,
broad patient populations from the National Hos-
pital Discharge Survey (NHDS) [15] and the Mary-
land Hospital Discharge Data Survey (MDHDDS)
[16]. We address both incidence and costs, partic-
ularly the incremental cost of candidiasis, as-
pergillosis, cryptococcosis and histoplasmosis.
 
Methods
 
Our study examined the incidence and first-year
costs of systemic fungal infections incurred from
the time of hospitalization. We used standard
methods for disease-cost estimation described else-
where [17–20]. Specifically, we computed the pro-
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jected 1998 incidence and attributable costs by
type of fungal infection and major diagnosis. We
applied an aggregate incidence-based approach us-
ing large national and state data sets to estimate
incidence rates and both hospital and post-hospi-
tal, first-year costs.
 
Incidence
 
We computed the US incidence of four types of
systemic fungal infections—candidiasis, histoplas-
mosis, aspergillosis, and cryptococcosis fungal in-
fections—using the 1994 and 1996 National Hos-
pital Discharge Survey (NHDS) [15] database. The
NHDS data set includes over 275,000 discharges
from a national sample of hospitals [21]. These
four fungal infections account for almost all cases
of systemic fungal infection, and candidiasis alone
accounts for up to 85% to 87% of these [9].
Systemic fungal infections were identified in the
NHDS database according to the International
Classification of Disease, Ninth Revision (ICD-9)
codes: candidiasis of the lung (112.4), disseminated
candidiasis (112.5), candidiasis of other specified
sites, including candidal endocarditis, candidal oti-
tis externa, candidal meningitis, candidal esoph-
agitis, candidal enteritis (112.8) and candidiasis of
unspecified site (112.9), infections by 
 
Histoplasma
capsulatum
 
 (115.0), infection by 
 
Histoplasma du-
boisii
 
 (115.1), aspergillosis (117.3) and cryptococ-
cosis (117.5). We searched for these ICD-9 codes
in any of the 15 positions for the diagnosis listed
at patient discharge.
Given that the NHDS is a nationally represen-
tative survey of hospital admissions, the total
number of hospitalized fungal infection cases from
the NHDS was used as the incidence or rate of in-
fection in the US population. The relative stan-
dard errors (RSE) for the NHDS fungal infection
estimates were also computed [21,22]. The 1996
NHDS systemic fungal incidence rate was pro-
jected and applied to the 1998 US population us-
ing the national census data [23].
 
Hospitalization Costs
 
Hospitalization costs were computed from the 1997
Maryland Hospital Discharge Data Set (MDHDDS)
[16]. The MDHDDS, compiled by the Maryland
Health Services and Cost Review Commission, con-
tains over 610,000 discharges from all nonfederal,
short-stay hospitals in Maryland. The MDHDDS
also contains information on patient demograph-
ics, itemized and total hospital charges, and primary
payer source. MDHDDS hospitalization charges
were converted to costs using hospital-specific
 
cost/charge ratios calculated within the data set.
MDHDDS has been used to estimate cost sources
in previous studies [24].
It is challenging to determine the cost of fungal
infections because of the difficulty of separating
these costs from those attributable to underlying
or associated diseases. For example, it is impossi-
ble to assign certain hospital days as fungal infec-
tion costs and others to costs of underlying dis-
eases such as HIV or cancer. Therefore, using a
case-control method, we estimated the incremen-
tal hospitalization costs due to systemic fungal in-
fection by comparing patients with fungal infec-
tions (cases) to patients with the same primary
diagnoses but without fungal infections (controls).
Four disease categories of primary diagnoses
commonly associated with fungal infections were
selected: HIV/AIDS, cancer/neoplasia, transplan-
tation, and “other.” Since the “other” group was
so large, we categorized the diagnoses for this
group into the 17 broad groups specified by the
ICD-9 diagnoses.
First, we selected a population of hospitalized
patients from the 1997 MDHDDS with systemic
fungal infections (cases) according to the ICD-9
codes listed above in any of the 15 possible vari-
able listings for diagnosis. Thereafter, we searched
the remaining 14 listings of possible diagnoses for
an associated diagnosis of HIV/AIDS, neoplasm,
transplant, or “any other” diagnosis. The controls
were defined as all other patients without fungal
infections and matched to the cases by their pri-
mary or first-listed diagnosis. Fourth, we deter-
mined the average cost per hospital stay for the
cases and controls in each fungal (candidiasis, his-
toplasmosis, aspergillosis, and cryptococcosis) and
diagnostic (HIV/AIDS, neoplasm, transplant, or
“any other”) group. We also computed the aver-
age hospital stays for both cases and controls. Fi-
nally, we subtracted the mean costs of the controls
from the mean costs of the cases to obtain the in-
cremental costs of the four fungal infections in
each diagnostic group.
Student’s 
 
t
 
-test was used to determine the sta-
tistical significance of the differences in mean hos-
pitalization costs between cases and controls for
each type of fungal infection and principal diag-
nosis. SAS statistical software (Cary, NC, version
6.12, 2000) and Microsoft Excel (Troy, New
York, version 9.0, 2000) were used for data analy-
ses [25,26].
Hospitalization costs included room charges,
radiology, operating room, drugs, lab tests, sup-
plies, therapy, and all other charges. Physician
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costs based on the Medicare fee schedule and de-
pendent on the average length of hospital stay
($109 
 

 
 $70 (LOS-1)) were also included. To esti-
mate the annual hospitalization cost of systemic
fungal infection for 1998, we projected the MDH-
DDS 1997 hospitalization cost by adjusting for
medical inflation [27] and applied it to the pro-
jected 1998 national incidence rates.
 
Post-Hospitalization Costs
 
Post-hospitalization costs were modeled from the
proportions of patients discharged in the 1996
NHDS discharge destination categories, i.e., death,
home, and short- or long-term care facilities. Those
discharged home accrued costs for home health
care (1.39 visits monthly), physician visits (1.73
visits monthly), lab tests, medications and general
follow-up care [28–31]. Physician costs were ob-
tained from the Medicare fee schedule and based
on CPT codes 99211–99215 [31]. The average an-
nual total home-care cost is $4512. Those dis-
charged to a long-term care facility were given
nursing home costs for the rest of the year, while
those discharged to short-term care were assumed
to have nursing home costs for half of the year.
Nursing home costs were determined from aver-
age annual costs of nursing home stays ($54,787/
year) in the Medicare/Medicaid population [32].
Patients who died in hospital only had hospital
costs attributed to the overall cost of their fungal
infection. All post-hospitalization costs were pro-
jected to 1998 values using the Consumer Price In-
dex [27].
Post-hospital drug costs were assumed to be in-
cluded in nursing home costs during both short-
and long-term care, but were included separately
for patients discharged to home and for the 6
months spent at home by patients discharged to
short-term care facilities. The outpatient drug ther-
apy was modeled using drug treatment guidelines
and expert clinicians [33–36]. Drug costs were de-
termined from the 1998 Red Book average whole-
sale price (AWP) [37].
Mortality rates were also considered in comput-
ing post-hospitalization costs. Literature-reported
mortality rates associated with fungal infections
are highly variable, ranging from 2.8% to 70%,
depending in part on the underlying comorbidities
and whether total or in-hospital rates are reported
[6,38–41]. Since approximately 7% of patients
admitted with fungal infections subsequently died
in the hospital, we attributed additional deaths to
those discharged alive to account for deaths over
the remaining year. We included an additional
15% post-hospitalization mortality for patients
going to home care and an additional 21% mor-
tality for patients discharged to either short- or
long-term nursing home care and varied these val-
ues in the sensitivity analysis.
 
Sensitivity Analyses
 
One-way sensitivity analyses were calculated for
incidence, mortality, and drug costs. For our anal-
ysis, we chose the best estimates for the base case.
High and low values for incidence, mortality, and
drug costs were used to calculate a range of cost
estimates. Incidence was varied by excluding ICD-
9112.8 and 112.9 (for candidiasis of other sites
and unspecified site, respectively) for the low-inci-
dence case (37,555) and by applying the higher
systemic fungal incidence from the MDHDDS (144,
462) for the high-incidence case. We also varied
mortality rates for the sensitivity analysis accord-
ing to the wide range of values quoted in the liter-
ature [7–9,38,41]. We assumed no post-hospital
deaths in the home-care group and 15% in nurs-
ing homes for the high-cost range and 35% and
48% mortality in the home-care and nursing home
groups, respectively, for the low-cost case. Outpa-
tient drug costs were also varied from the base
case using the range of doses and lengths of drug
treatment recommended in the treatment guide-
lines [33–36].
 
Results
 
Incidence
 
Table 1 shows the rates for fungal infections from
the NHDS data, reported per million US popula-
tion and per 10,000 hospital patients in 1994 and
in 1996. Candidiasis is the most frequent systemic
fungal infection, accounting for as much as 80%
of reported cases. Histoplasmosis has the lowest
rate, most likely because of the endemic nature of
the disease
 
.
 
 The incidence of hospitalization for
systemic fungal infections was 306 per million in
1996.
Much of the clinical, epidemiological, and cost
literature on fungal infections focuses on the oc-
currence in patients with three comorbid diag-
noses: HIV/AIDS, neoplasia, or transplantation.
However, our analyses show that these diagnoses
are associated with only 44% of all hospitaliza-
tions for systemic fungal infection. HIV/AIDS and
neoplasia are the diagnoses associated with the
highest proportions (22% and 21%, respectively)
of systemic fungal diseases. Patients with HIV/
AIDS account for 79% of the hospitalizations for
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cryptococcosis, and those with neoplasms account
for as much as 42% of the hospitalizations for sys-
temic aspergillosis. Transplant patients, another
patient group prone to systemic fungal infections,
account for only 1% of the total patients diag-
nosed with fungal infections.
The remaining 56% of patients hospitalized for
fungal infections, exclusive of HIV/AIDS, neo-
plasms, or transplants belong to the “other diag-
nosis” group. In the “other” category, patients di-
agnosed with diseases of the respiratory system
comprise the highest proportion (15%) of all fun-
gal infections. Patients with comorbid diagnoses
involving the respiratory tract account for 17% of
cases of systemic candidiasis, 15% of histoplas-
mosis, 18% of all aspergillosis and only 0.7% of
cryptococcosis. Another 14% of patients with sys-
temic fungal infections have concomitant “other
diagnoses” of infectious and parasitic diseases (not
including fungal disease), followed by diseases of
the digestive system (7%), disease of the circula-
tory system (5%), injuries and poisonings (5%),
and miscellaneous diagnoses (10%).
 
Inpatient Hospital Costs by Type of Infection and 
Associated Diagnoses
 
The mean cost comparison between cases and
controls is enumerated in Table 2. Projected to
1998, the incremental, weighted, average hospital-
ization cost per person attributable to systemic
 
Table 1
 
Incidence rates of hospitalized fungal infection cases by year and type of infection. Relative standard error (RSE) of N 
expressed as percent of the estimate, computed as described in [21,22]
 
NHDS* 1996 NHDS 1994
N RSE*
Rate per million
US population
Rate per 10,000
hospital patients N RSE
 
†
 
Rate per million
US population
Rate per 10,000
hospital patients
Total 82,608 7.52 305.62 27.05 78,928 10.89 303.23 25.59
Candidiasis 61,680 8.43 228.19 20.19 62,815 12.04 241.33 20.37
Histoplasmosis 3,681 31.28 13.62 1.21 4,950 40.58 19.02 1.60
Aspergillosis 9,261 19.93 34.26 3.02 5,195 39.62 19.96 1.68
Cryptococcosis 7,987 21.41 29.55 2.61 5,968 36.99 22.93 1.93
 
*Computed as described in [22].
 
†
 
Computed as described in [21].
NHDS, National Hospital Discharge Survey.
 
Table 2
 
Hospitalization mean and incremental cost per person between patients with and without fungal infection by 
underlying morbidity from the analysis of the 1997 MDHDDS
 
Fungal infection
Underlying
morbidity
Mean cost without
infection
US$ (SEM)
Mean cost with
infection
US$ (SEM) Prob
 

 
T
Incremental
costs
US$
Incremental cost
projected to 1998
Weighted average*
US$
Candidiasis 14,804
HIV 9036 (155) 12288 (745) 0.0001 3256 3356
Neoplasm 8975 (53) 26188 (1757) 0.0001 17212 17763
Transplant 72706 (2344) 119926 (12721) 0.0001 47221 48732
Other 7024 (16) 22752 (934) 0.0001 15728 16231
Histoplasmosis 329
HIV 9247 (153) 10312 (2948) 0.8072 7621 1673
Neoplasm 9104 (54) 11971 (2689) 0.5283 2868 2960
Transplant — — — — —
Other 7070 (16) 6354 (971) 0.4665
 

 
739
 

 
739
Aspergillosis 36,867
HIV 9160 (150) 40469 (8041) 0.0014 31309 32311
Neoplasm 9045 (53) 55474 (8056) 0.0001 46429 47915
Transplant 73980 (2309) 157929 (65129) 0.0096 83949 86635
Other 7066 (16) 31916 (4629) 0.0001 24850 25645
Cryptococcosis 6,328
HIV 9122 (156) 12462 (717) 0.0000 3340 3447
Neoplasm 9097 (54) 27010 (9558) 0.0737 14684 15154
Transplant — — — — —
Other 7069 (16) 25542 (6135) 0.0051 18473 19064
Total 15,813
 
*Weighted averages per incident case of the incremental cost projected to 1998.
MDHDDS, Maryland Hospital Discharge Data Survey.
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candidiasis, histoplasmosis, aspergillosis and cryp-
tococcosis is $15,813 (range from $15,646 to
$16,758). Aspergillosis accounts for the largest in-
cremental per-person hospitalization costs of all
fungal infections ($36,867). Candidiasis also ac-
counts for a high incremental cost of $14,804.
The incremental hospitalization cost for crypto-
coccosis is $6328, while the incremental hospital-
ization cost for histoplasmosis is only $329 per
case.
Transplant patients have the highest mean ad-
ditional hospitalization costs per person attribut-
able to any type of fungal infection, $53,470. Pa-
tients with neoplasms incur an additional cost per
person of $21,571, while those with a diagnosis of
HIV/AIDS incur much lower per-person costs for
fungal infections ($4128). These three diagnoses,
however, represent only 44% of patients hospital-
ized with systemic fungal infections. The remain-
ing patients, with fungal infections from all “other
diagnoses” incur an additional $16,506 per per-
son for hospitalization costs on average.
Statistical analyses reveal that the average dif-
ferences in hospital costs between patients with
and without fungal infections matched by diagno-
sis (cases and controls) are statistically significant
(
 
p
 
 
 

 
 .01) (Table 2) for all systemic fungal infec-
tions and all comorbid diagnoses except for cryp-
tococcosis in patients with neoplasms and patients
with histoplasmosis in any diagnostic category,
where the differences were not significant. The in-
cremental hospitalization cost due to histoplasmo-
sis is not statistically significant, most likely because
of the small number of cases of histo-plasmosis
(
 
n
 
 
 

 
 47) in the 1997 MDHDDS used to estimate
costs.
Over all diagnoses and types of fungal infec-
tions, the room rate contributes the most to total
hospitalization costs (47%). Drug costs account
for 17% of total hospitalization costs across all
fungal types and laboratory costs contribute sig-
nificantly (11%) to the total costs. Other factors
contribute between 3% and 6% to total hospital-
ization costs. Patients with aspergillosis have the
lengthiest additional hospital stay (19 days), and
those with candidiasis stay an average of 14 addi-
tional days in the hospital.
We also investigated who was paying the larg-
est burden of the hospitalization costs for these
fungal infections based on the NHDS 1996 data.
Government insurance is primarily responsible,
covering 67% of hospitalization costs, with Medi-
care paying 44% and Medicaid, 20%. Private in-
surance covers 24% and the recipient of services
 
pays only 3%; the remainder is not specified.
Medicare pays for almost half of the total hospi-
talization costs for candidiasis and aspergillosis.
The cost burden of histoplasmosis is borne prima-
rily by “other private insurance” (32%) and Med-
icaid (29%) and to a lesser extent, Medicare (20%)
and self-pay (13%). Fifty-four percent of the costs
associated with cryptococcosis are paid by Medic-
aid and to a lesser extent by Medicare (19%),
other government payers (19%), and other private
insurance (17%).
 
Post-Discharge Status and Hospital Mortality
 
Discharge status obtained from the 1996 NHDS
data reveals that 75% of patients are discharged
to home, 18% go to nursing home care (6% short-
term and 12% long-term), and 6.8% of patients
die in the hospital. Our hospital mortality rates are
comparable to one previously reported in the liter-
ature (9%) for nosocomial fungal infections [42].
Discharge status varies by type of fungal infec-
tion. Patients with cyptococcosis infections have
the highest in-hospital death rate per admission
(16%), followed by candidiasis (6.3%). Aspergil-
losis and histoplasmosis are associated with simi-
lar inpatient mortality rates of 3.9% and 3.4% of
hospital deaths, respectively. Patients with systemic
aspergillosis are most frequently discharged to
home (86.6%). The majority of patients diag-
nosed with systemic histoplasmosis, candidiasis,
or cryptococcosis were also discharged home (80.6%,
73.4%, and 71.8%, respectively). The largest pro-
portion (14.6%) of patients discharged to long-
term nursing homes are those diagnosed with sys-
temic candidiasis. Only 1% to 6% of patients with
other fungal types are discharged to nursing homes.
 
Outpatient Costs
 
The cost of post-hospitalization outpatient care in
the first year is $1192 million for all patients,
which accounts for 47% of total costs (Table 3).
Outpatient costs and costs per prevalent case are
highest for candidiasis patients. Nursing home care
accounts for the largest proportion (57%) of all
outpatient costs ($676 million) following discharge
from hospital for systemic fungal infections, de-
spite being the final destination for only 18% of
the discharges.
Additional outpatient medication costs amount
to $236 million or $2859 annually per person.
The highest average annual drug cost per person
($23,295) is associated with aspergillosis. The use
of liposomal amphotericin B in this group ac-
counts for some of the elevated drug cost, since
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our model estimates that 40% of patients dis-
charged from the hospital take liposomal ampho-
tericin B for an average of 70 days. Drug costs are
much lower for cryptococcosis, but higher for histo-
plasmosis ($6 million) despite its low incidence.
When 17% of the inpatient costs attributed to in-
patient medication ($225 million) is added to the
outpatient drug costs ($236 million), the total
drug cost constitutes 18% of total direct costs as-
sociated with all systemic infections in the first
year.
 
Total Costs
 
The total direct incremental cost of the first year
of treatment of systemic fungal infections in the
United States is $2.6 billion. Figure 1 divides the
total cost into hospitalization and post-hospital-
ization costs, including nursing home, home health
care, and outpatient medications. Hospitalization
(including physician fees) contributes the highest
proportion to total cost, or 54% ($1.4 billion).
For the almost 15,000 patients (18% of the hospi-
talized sample) discharged to either short-term or
long-term nursing home care, the additional nurs-
ing home costs account for 26% of total costs
($676 million), $535 million for long-term nurs-
ing home care, and $142 million for short-term
nursing home care. Among the 75% of patients
discharged to home, the additional home-health-
care cost (including physician visits, lab tests, and
home-care workers) is $280 million. Outpatient
medications contribute significantly ($236 million
or 11%) to the total cost, but total inpatient and
outpatient drug costs account for 18% of the total
costs.
As shown in Table 3, total costs are highest for
candidiasis ($1.7 billion), primarily because of its
high incidence. Candidiasis accounts for 75% of all
 
systemic fungal infections and 66% of the total
cost of these. Aspergillosis accounts for 26% ($674
million) of costs, and cryptococcosis and histoplas-
mosis costs are $151 million and $53 million, re-
spectively, representing only 6% and 2% of all costs
for systemic fungal infections. Per-person weighted
average annual costs were $31,193. This per-per-
son cost is highest for aspergillosis at $72,792,
which is more than twice the overall average. The
average incremental per-person hospitalization costs
account for most of this difference, because the
high inpatient mortality associated with aspergillo-
sis reduces outpatient cost.
 
Sensitivity Analysis
 
Because of the large variation in reported inci-
dence and mortality rates [7–9,42,43], we calcu-
late total costs using ranges of incidence and mor-
tality around the base case as shown in Table 4.
Varying the fungal incidence from 161 per million
to 534 per million resulted in a total cost range be-
tween $978 million and $6 billion. Changing the
mortality rates for patients discharged to home
from 0% to 35% has very little effect (3%) on to-
tal direct costs ($1525–$1578 million). However,
 
Table 3
 
Projected 1998 total costs and average per-incident case (PIC) by fungal infection
 
Total
(N 
 

 
 82608)
Candidiasis
(N 
 

 
 61680)
Histoplasmosis
(N 
 

 
 3681)
Aspergillosis
(N 
 

 
 9261)
Cryptococcosis
(N 
 

 
 7987)
Total cost
(millions $) PIC ($)
Total cost
(millions $) PIC ($)
Total cost
(millions $) PIC ($)
Total cost
(millions $) PIC (*$)
Total cost
(millions $) PIC (*$)
Total costs 2,576.75 31,193 1,698.85 27,543 52.54 14,275 674.12 72,792 151.23 18,934
Total inpatient 1,384.35 16,758 971.04 15,743 3.96 1,076 351.19 37,921 58.15 7,281
Hospital 1,306.29 15,813 913.11 14,804 1.21 329 341.42 36,867 50.54 6,328
Physician 78.06 945 57.93 939 2.75 747 9.77 1,054 7.61 953
Total outpatient 1,192.39 14,434 727.81 11,800 48.58 13,199 322.92 34,871 93.07 11,653
Home care 279.78 3,387 208.90 3,387 12.47 3,387 31.36 3,387 27.05 3,387
Drugs 236.14 2,859 13.81 224 5.97 1,622 215.73 23,295 0.62 78
Short-term care 141.95 1,718 105.99 1,718 6.32 1,718 15.91 1,718 13.72 1,718
Long-term care 534.52 6,470 399.11 6,470 23.82 6,470 59.92 6,470 51.68 6,470
Figure 1 Total costs by type of cost.
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changes in mortality estimates in the nursing home
from 15% to 48% have a greater (22%) effect on
total costs ($574–$699 million). Changes in the
estimated duration of drug treatment changed to-
tal costs by only 5%. Overall, the lowest total esti-
mate is $853,000 or $22,700 per prevalent case
while the highest total estimate is $6.1 billion or
$42,500 per prevalent case.
 
Discussion
 
The cost burden of fungal infections nationally is
high, with an annual cost of $2.6 billion. Total US
health expenditures in 1998 were $1.1 trillion
[44]. Thus, approximately 0.24% of total US
health expenditures are spent on systemic fungal
infections. This is high considering that only
0.03% of the total US population contracts fungal
infections. The average annual health expenditure
per person in the United States is $4,094, while
the average added expenditures for patients with
fungal infections is $31,200 per person, almost
eight times greater.
The cost estimates used in this paper are based
on the best available resources for developing na-
tional estimates, such as the NHDS, the Medicare
fee schedule, and the Medicare national nursing
home survey. The large sample sizes are a strength
of these data sets because of the low incidence
 
rates of fungal infections. However, several quali-
fications should be noted:
1. All fungal infections as tallied in the NHDS by
the corresponding ICD-9 codes were assumed
to include both nosocomial and community-
acquired cases.
2. Although hospital rates were used to estimate
incidence, some community-acquired cases might
not have been admitted to the hospital and
therefore our estimates may be low. We ac-
counted for this in the sensitivity analyses by
increasing the total number of systemic infec-
tions from 82,608 to 144,462 cases.
3. Attributable cost is estimated by comparing the
average costs of hospitalization by matching
patients with the same diagnosis with and with-
out fungal infections. However, we were only
able to match patients based on admitting di-
agnoses, and the patients might differ on fac-
tors other than fungal infections. While most
differences in severity of disease diagnosis may
be attributable to the fungal infection itself,
other disease factors might contribute to and
bias the results. Therefore, the cost attributable
to systemic fungal infections should be consid-
ered a maximum estimate and further study on
better-matched cases should be considered.
Our incidence figures are comparable to those
in the literature when we take into consideration
both the location of the studies and the diagnoses
included. One such study by Rees et al. [9] based
in the San Francisco Bay Area reported a rate for
candidiasis of 72.8 per million, which is much
lower than the rate we observed for candidiasis of
305.6 per million. However, when we recalculated
our incidence rates using the same ICD-9s as those
in the Rees study, the candidiasis incidence was
59.3 per million, which is more comparable. Rees
et al. [9] also reported rates somewhat lower than
those reported here for aspergillosis (12.4 vs. 19.2
per million) which may be a result of stricter diag-
nostic criteria requiring two positive bronchoalve-
olar lavages. When determining cost, we chose a
more inclusive definition or diagnostic criteria.
Most reports on fungal infections focus on
rates, costs, and treatments for fungal infections
associated with three main diagnoses—HIV/AIDS,
neoplasia, and transplantation—because of the
high prevalence of fungal infections in these diag-
noses [4,12–14,45–48]. However, we found that
fungal infections associated with all other diag-
noses make up 55% of all cases requiring hospi-
talization for such infections, higher than in the
 
Table 4
 
Sensitivity analysis: Effects of variations in 
incidence, mortality and outpatient drug treatment
duration on total costs of fungal infections
 
Variations in: Low case* Base case
 
†
 
High case
 
‡
 
Incidence: 37,555  82,608 144,462
Total costs (millions $) 978 2,577 6,000
Cost/person ($) 26,000 31,200 41,500
Home-care mortality (%): 35 15 0
Total home-care costs
(millions $) 1,525 1,555 1,578
Cost/person ($) 24,600 25,100 25,400
Nursing-home mortality (%): 48 21 15
Total nursing-home costs
(millions $) 574 676 699
Cost/person ($) 38,500 45,300 46,800
Outpatient drug duration:
Total drug cost (millions $) 171.1 236.1 301.2
Total costs (millions $) 2,512 2,577 2,642
Cost/person ($) 30,409 31196 31982
All factors: 37,555 82,608 144,462
Total costs (millions $) 853 2,577 6,144
Cost/person ($) 22,700 31,200 42,500
 
*ICD-9s restricted to 112.4 and 112.5 only.
 
†
 
ICD-9s included 112.4, 112.5, 112.8, and 112.9 and projected 1998 cases from
NHDS 1996.
 
‡
 
Projected 1998 cases from Maryland 1997 data.
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other three diagnoses combined. There have been
several studies on the additional risk factors for
susceptibility to nosocomial fungal infections from
causes such as central lines, urinary catheters, me-
chanical ventilation and nosocomial transmission
[10,49–51], antifungal drug resistance [52], neu-
tropenia [53] and immunosupression [54,55]. The
National Nosocomial Infections Surveillance (NNIS)
tracks rates of nosocomial infections in postsurgi-
cal intensive-care units and among patients using
catheters and central lines [56]
Subsequent studies are needed to further ex-
plore the incidence of and preventive treatments
for fungal infections among patients in the “other”
diagnostic categories (respiratory and circulatory
diseases), who may also be neutropenic or immu-
nocompromised. NNIS surveys do include all high-
risk patients, but more attention should be given
to prevention of these risk factors in “other” diag-
nostic groups as well.
In our analysis of incidence in the 1994 and
1996 NHDS, we found no significant change in
incidence between those 2 years despite previous
reports in the literature that cited large increases
in the incidence of systemic fungal infections in
the 1980s [1,2]. Further studies are required to de-
termine whether the incidence of systemic fungal
diseases has stabilized in recent years, influenced
perhaps by better preventive measures and treat-
ments for neutropenia.
 
The authors wish to thank Dr. Elaine C. Meng for re-
viewing the manuscript.
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